Findings

What do systematic reviews say?

885 questions · 903 findings · 72 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 106 · 11.7%GRADE not reported 45 · 5%Very low 114 · 12.6%Low 238 · 26.4%Moderate 314 · 34.8%High 86 · 9.5%

Inhaled corticosteroids vs placebo

Lung function (other indices) ‐ TLC % predicted (end of study values) · people with bronchiectasis

1 finding from 1 review

Inhaled corticosteroids for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 57 participants
Low

Inhaled corticosteroids vs placebo

Exacerbations · people with bronchiectasis

1 finding from 1 review

Inhaled corticosteroids for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 127 participants
Low

Inhaled corticosteroids vs placebo

Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis

Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).

1 finding from 1 review

Inhaled corticosteroids for bronchiectasis 2018 · Cochrane Headline outcomes only
OR 0.94 [0.45, 1.96]
2 studies · 156 participants
Low

Inhaled corticosteroids vs placebo

FEV1 % predicted: absolute change from baseline · people with bronchiectasis

1 finding from 1 review

Inhaled corticosteroids for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Low

Inhaled corticosteroids vs placebo

FVC (% predicted) Change from baseline · people with bronchiectasis

1 finding from 1 review

Inhaled corticosteroids for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Low

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

Eradication of P aeruginosa from the respiratory tract: proportion with positive respiratory culture for P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Inhaled colistin plus oral ciprofloxacin showed no clear difference in eradication of P aeruginosa from the respiratory tract: proportion… compared with inhaled tobramycin (TNS) plus oral ciprofloxacin (low certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
OR 1.11 [0.64, 1.92]
1 study · 223 participants
Low

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

Growth and nutritional status · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 205 participants
Moderate

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

Adverse effects of antibiotics: leading to trial discontinuation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 223 participants
Moderate

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Eradication of P aeruginosa from the respiratory tract: proportion of participants with a negative culture for PA during the 28 days following treatment · children and adolescents with cystic fibrosis

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 139 participants
Very low

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

FEV1 % predicted · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

FVC · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Growth and nutritional status · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

Adverse effects of antibiotics: number of participants reporting a serious adverse event · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Combination inhaled therapy vs SABA

Hospital admissions · Adults with acute asthma

Combination inhaled therapy probably leads to lower hospitalisation compared with SABA alone (moderate certainty).

1 finding from 1 review

Combined inhaled beta‐agonist and anticholinergic agents for emergency management in adults with asthma 2017 · Cochrane Headline outcomes only
RR 0.72 [0.59, 0.86]
16 studies · 2120 participants
Moderate